StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Respiratory & Immunology (R&I) by Quarter

Respiratory & Immunology (R&I) — Worldwide YoY actual (%) (%)

QuarterlyAnnual

AstraZeneca Respiratory & Immunology (R&I): 11.0% in Q2 2026, unchanged from a year earlier.

Latest, Q2 2026
11.0%
Period ended Jun 30, 2026
Change on a year earlier
0.0 pts
11.0% in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| R&I | 2,207 | | 11 | | 9 | | 982 | | - | | 490 | | 29 | | 24 | | 509 | | 21 | | 16 | | 226 | | 9 | | 11”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Therapy Area Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRespiratory & Immunology (R&I) — Worldwide YoY actual (%) (%)Year on yearSource
Q2 2026Jun 30, 202611.0%0.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202610.0%+2.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20258.0%-17.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202514.0%-12.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202511.0%-10.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 20258.0%-6.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202425.0%+15.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202426.0%+24.0 ptsForm 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202421.0%+14.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202414.0%+9.0 ptsForm 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202310.0%+19.0 ptsForm 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20232.0%+6.0 ptsForm 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20237.0%+10.0 ptsForm 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 20235.0%+7.0 ptsForm 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022-9.0%-13.0 ptsForm 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022-4.0%-32.0 ptsForm 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Respiratory & Immunology (R&I) (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-ri-world-act-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.